Fosinopril
Fosinopril
(IUPAC ) ime
(2S ,4S )-4-cikloheksil-1-(2- {[2-metil-1-(propanoiloksi)propoksi](4-fenilbutil)fosforil}acetil)pirolidin-2-karboksilna kiselina
Klinički podaci
Robne marke
Monopril
AHFS/Drugs.com
Monografija
MedlinePlus
a692020
Identifikatori
CAS broj
98048-97-6
ATC kod
C09 AA09
PubChem [ 1] [ 2]
55891
DrugBank
DB00492
ChemSpider [ 3]
10482016
UNII
R43D2573WO Y
KEGG [ 4]
D07992 Y
ChEMBL [ 5]
CHEMBL1201310 Y
Hemijski podaci
Formula
C 30 H 46 N O 7 P
Mol. masa
563,663 g/mol
SMILES
eMolekuli & PubHem
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39-/m1/s1 Y Key: BIDNLKIUORFRQP-YYTCENNOSA-N Y
Farmakokinetički podaci
Bioraspoloživost
~36%
Vezivanje za proteine plazme
87% (fosinoprilat)
Metabolizam
hepatički
Poluvreme eliminacije
12 sata (fosinoprilat)
Izlučivanje
renalno
Farmakoinformacioni podaci
Trudnoća
D(AU )
Pravni status
℞ Prescription only
Način primene
oralno
Fosinopril je inhibitor angiotenzin konvertujućeg enzima (AKE) [ 6] koji se koristi u tretmanu hipertenzije i pojedinih tipova hroničnog zatajenja srca . Fosinopril je jedini ACE inhibitor na tržištu (Monopril ) koji sadrži fosfinat.
Fosinoprilat, aktivna forma fosinoprila.
Fosinoprilat and Fosinopril
Fosinoprilat manifestuje isti problem kao i enalaprilat i drugi ACE inhibitori koji sadrže karboksil, slabu oralnu bioraspoloživost . Dodatak hidrofobnog bočnog lanca moduliše jonizacione karakteristike molekula, i povećava njegovu bioraspoloživost. Fosinopril se administrira kao prolek i konvertuje se in vivo u aktivnu formu fosinoprilat.
Osobine
Reference
↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.” . Drug Discov Today 15 (23-24): 1052-7. DOI :10.1016/j.drudis.2010.10.003 . PMID 20970519 . edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4 : 217-241. DOI :10.1016/S1574-1400(08)00012-1 .
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining” . J Cheminform 2 (1): 3. DOI :10.1186/1758-2946-2-3 . PMID 20331846 . edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG” . Yeast 17 (1): 48–55. DOI :10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H .
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI :10.1093/nar/gkr777 . PMID 21948594 . edit
↑ Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, Tu JV (May 2008). „Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure” . CMAJ 178 (10): 1303–11. DOI :10.1503/cmaj.060068 . PMC 2335176 . PMID 18458262 .
↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods” . J. Phys. Chem. A 102 : 3762-3772. DOI :10.1021/jp980230o .
↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices” . Chem Inf. Comput. Sci. 41 : 1488-1493. DOI :10.1021/ci000392t . PMID 11749573 . edit
↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties” . J. Med. Chem. 43 : 3714-3717. DOI :10.1021/jm000942e . PMID 11020286 . edit
Spoljašnje veze